Evidence map›Paper›PMID 27727327›Full record

ArticlePloS one2016

Amelioration of Renal Inflammation, Endoplasmic Reticulum Stress and Apoptosis Underlies the Protective Effect of Low Dosage of Atorvastatin in Gentamicin-Induced Nephrotoxicity.

Krit Jaikumkao, Anchalee Pongchaidecha, La-Ongdao Thongnak, Keerati Wanchai, Phatchawan Arjinajarn, Varanuj Chatsudthipong, Nipon Chattipakorn, Anusorn Lungkaphin

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
7.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 78 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Life (Basel, Switzerland) · 2022
    Article
  15. Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  16. Nephroprotective Effect ofJournal of toxicology · 2022
    Article
  17. Antioxidative and Anti-Inflammatory Protective Effects ofOxidative medicine and cellular longevity · 2022
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Krit JaikumkaoDepartment of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Anchalee PongchaidechaDepartment of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
La-Ongdao ThongnakDepartment of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Keerati WanchaiDepartment of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Phatchawan ArjinajarnDepartment of Biology, Faculty of Science, Chiang Mai University, Chiang Mai, Thailand.
Varanuj ChatsudthipongDepartment of Physiology, Faculty of Science, Mahidol University, Bangkok, Thailand.
Nipon ChattipakornDepartment of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Anusorn LungkaphinDepartment of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Chiang Mai University · THMahidol University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gentamicin is a commonly used aminoglycoside antibiotic. However, its therapeutic use is limited by its nephrotoxicity. The mechanisms of gentamicin-induced nephrotoxicity are principally from renal inflammation and oxidative stress. Since atorvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, exerts lipid-lowering effects, antioxidant, anti-inflammatory as well as anti-apoptotic effects, this study aimed to investigate the protective effects of atorvastatin against gentamicin-induced nephrotoxicity. Male Sprague Dawley rats were used and nephrotoxicity was induced by intraperitoneal injection of gentamicin, 100 mg/kg/day, for 15 days. Atorvastatin, 10 mg/kg/day, was administered by orally gavage 30 min before gentamicin injection on day 1 to 15 (pretreatment) or on day 10 to15 (delayed treatment). For only atorvastatin treatment group, it was given on day 1 to 15. At the end of the experiment, kidney weight, blood urea nitrogen and serum creatinine as well as renal inflammation (NF-κB, TNFαR1, IL-6 and iNOS), renal fibrosis (TGFβ1), ER stress (calpain, GRP78, CHOP, and caspase 12) and apoptotic markers (cleaved caspase-3, Bax, and Bcl-2) as well as TUNEL assay were determined. Gentamicin-induced nephrotoxicity was confirmed by marked elevations in serum urea and creatinine, kidney hypertrophy, renal inflammation, fibrosis, ER stress and apoptosis and attenuation of creatinine clearance. Atorvastatin pre and delayed treatment significantly improved renal function and decreased renal NF-κB, TNFαR1, IL-6, iNOS and TGFβ1 expressions. They also attenuated calpain, GRP78, CHOP, caspase 12, Bax, and increased Bcl-2 expressions in gentamicin-treated rat. These results indicate that atorvastatin treatment could attenuate gentamicin-induced nephrotoxicity in rats, substantiated by the reduction of inflammation, ER stress and apoptosis. The effect of atorvastatin in protecting from renal damage induced by gentamicin seems to be more effective when it beginning given along with gentamicin or pretreatment.

Indexed as

AnimalsApoptosisAtorvastatinbcl-2-Associated X ProteinBlood Urea NitrogenCaspase 12CreatinineDose-Response Relationship, DrugDrug Administration ScheduleEndoplasmic Reticulum Chaperone BiPEndoplasmic Reticulum StressGentamicinsHeat-Shock ProteinsInterleukin-6KidneyMaleAtorvastatinbcl-2-Associated X ProteinCaspase 12CreatinineEndoplasmic Reticulum Chaperone BiPGentamicinsHeat-Shock ProteinsInterleukin-6NF-kappa BNitric Oxide Synthase Type IIProtective AgentsProto-Oncogene Proteins c-bcl-2Transforming Growth Factor beta1

Identifiers

PMID27727327
PMCPMC5058561
OpenAlexW2530154446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.